Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes MellitusComparison with Other Oral Antihyperglycaemic Agents

被引：0
|
作者：
Giuseppe Derosa
机构：
[1] University of Pavia,Department of Internal Medicine and Therapeutics
来源：
Drugs | 2010年 / 70卷
关键词：
Metformin; Rosiglitazone; Pioglitazone; Acarbose; Sitagliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Diabetes mellitus is a debilitating disease that is estimated to affect 366 million people by the year 2030. Type 2 diabetes mellitus (T2DM) is characterized by a progressive decline in pancreatic β-cell function and increased insulin resistance, and accounts for approximately 90% of people with diabetes. Oral antihyperglycaemic agents are extensively used in the treatment of T2DM. Thiazolidinediones are insulin sensitizers developed specifically for T2DM, which act via activation of peroxisome proliferator-activated receptors (PPARs). Pioglitazone is a thiazolidinedione that displays high affinity for PPARγ1 and PPARγ2, which are predominately expressed in adipose tissue.
引用
收藏
页码：1945 / 1961
页数：16
相关论文
共 50 条
  • [21] Meta-analysis of studies examining medication adherence to oral antihyperglycaemic agents in type 2 diabetes
    Tunceli, K.
    Cartier, S. E.
    Rosen, V. M.
    Zarotsky, V.
    Iglay, K.
    Rajpathak, S. N.
    Radican, L.
    DIABETOLOGIA, 2013, 56 : S119 - S119
  • [22] Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
    Kjeld Hermansen
    Lene S. Mortensen
    Drug Safety, 2007, 30 : 1127 - 1142
  • [23] Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus
    Hermansen, Kjeld
    Mortensen, Lene S.
    DRUG SAFETY, 2007, 30 (12) : 1127 - 1142
  • [24] Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes
    DeFronzo, R. A.
    Burant, C. F.
    Fleck, P.
    Wilson, C.
    Mekki, Q.
    Pratley, R. E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (05): : 1615 - 1622
  • [25] Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice
    Schöfl, C
    Lübben, G
    CLINICAL DRUG INVESTIGATION, 2003, 23 (11) : 725 - 734
  • [26] Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice
    Christof Schöfl
    Georg Lübben
    Clinical Drug Investigation, 2003, 23 : 725 - 734
  • [27] Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes
    Belcher, G
    Lambert, C
    Edwards, G
    Urquhart, R
    Matthews, DR
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 70 (01) : 53 - 62
  • [28] REASONS OF UK GENERAL PRACTITIONERS FOR PRESCRIBING 15-OR 30-MG OF PIOGLITAZONE IN COMBINATION WITH OTHER ORAL ANTIHYPERGLYCAEMIC AGENTS
    Tunceli, K.
    Lento, K.
    Zhang, Q.
    Jameson, K.
    Meiler, S.
    Davies, M. J.
    Steinberg, H.
    Brodovicz, K.
    Radican, L.
    Sinclair, A.
    VALUE IN HEALTH, 2011, 14 (07) : A486 - A486
  • [29] Efficacy and Safety of Colesevelam in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus
    Rosenstock, J.
    Truitt, K. E.
    Baz-Hecht, M.
    Ford, D. M.
    Tao, B.
    Chou, H. S.
    HORMONE AND METABOLIC RESEARCH, 2014, 46 (13) : 943 - 949
  • [30] The efficacy of pioglitazone compared to metformin in drug naive patients with type 2 diabetes
    Schernthaner, G
    Edwards, G
    Lee, C
    Tan, M
    Herz, M
    DIABETES, 2003, 52 : A455 - A455
12345